Investigational Drug Information for HMPL-689
✉ Email this page to a colleague
What is the drug development status for HMPL-689?
HMPL-689 is an investigational drug.
There have been 6 clinical trials for HMPL-689.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 1st 2023.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Follicular, and Lymphoma, B-Cell, Marginal Zone. The leading clinical trial sponsors are Hutchison Medipharma Limited, Hutchmed, and [disabled in preview].
Summary for HMPL-689
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-02-01) |
| Vendors | 9 |
Recent Clinical Trials for HMPL-689
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma | Hutchmed | Phase 2 |
| HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI | Hutchmed | Phase 1 |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | Hutchison Medipharma Limited | Phase 2 |
Clinical Trial Summary for HMPL-689
Top disease conditions for HMPL-689
Top clinical trial sponsors for HMPL-689
US Patents for HMPL-689
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
